文献速递衰弱、肌少症与跌倒老年慢病共病管理

衰弱对台湾2型糖尿病患者GLP-1受体激动剂与SGLT2抑制剂疗效和安全性的影响:回顾性全国纵向研究

Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.
PubMed 文献 · Lancet Healthy Longev · 2024-09-13

该回顾性全国纵向研究基于台湾全民健康保险数据库,纳入2017至2019年新启用GLP-1受体激动剂或SGLT2抑制剂的2型糖尿病患者,按多病衰弱指数分为健康、轻度衰弱、中重度衰弱三个亚组,经倾向评分匹配后比较两组临床结局。结果显示各衰弱亚组中多数结局相当,但GLP-1受体激动剂组在轻度衰弱亚组中严重高血糖住院风险更高,且在健康、轻度衰弱、中重度衰弱亚组中透析或肾移植风险均更高。

要点

  • 各衰弱亚组中,GLP-1受体激动剂与SGLT2抑制剂使用者多数临床结局相当。
  • 轻度衰弱亚组中,GLP-1受体激动剂组严重高血糖住院风险高于SGLT2抑制剂组。
  • 健康、轻度衰弱、中重度衰弱亚组中,GLP-1受体激动剂组透析或肾移植风险均更高。

核心结论

  • 在2型糖尿病患者中,除严重高血糖住院和透析或肾移植风险外,GLP-1受体激动剂与SGLT2抑制剂在各衰弱亚组的临床结局总体相当。
  • GLP-1受体激动剂相比SGLT2抑制剂与更高的透析或肾移植风险相关,该风险在健康、轻度衰弱和中重度衰弱亚组中均存在。

研究设计与样本

  • 回顾性、全国性、纵向研究,数据来自台湾全民健康保险数据库,纳入2017年1月1日至2019年12月31日新启用GLP-1受体激动剂或SGLT2抑制剂的≥20岁2型糖尿病患者。
  • 排除索引日期前1年内诊断癌症、因肾衰竭接受透析或曾处方GLP-1受体激动剂或SGLT2抑制剂者;死亡数据来自台湾死亡登记库。
  • 按多病衰弱指数将合格个体分为健康、轻度衰弱、中重度衰弱三个亚组,并在每个亚组内进行1:1倾向评分匹配。
  • 采用次分布风险模型比较各衰弱亚组中GLP-1受体激动剂与SGLT2抑制剂使用者的结局风险。

主要发现

  • 匹配后,健康、轻度衰弱、中重度衰弱亚组分别有11 882对、7 210对、3 414对GLP-1受体激动剂与SGLT2抑制剂使用者。
  • 各衰弱亚组中,除以下两项外,GLP-1受体激动剂与SGLT2抑制剂使用者的所有临床结局均相当。

关键数值与推荐

  • 衰弱分层依据多病衰弱指数分为健康、轻度衰弱、中重度衰弱三个亚组。
  • 主要结局包括三点主要不良心血管事件(非致死性急性心肌梗死、非致死性卒中、致死性心血管病)、全因死亡、心力衰竭住院、透析或肾移植、严重糖尿病足并发症、视网膜病变、严重高血糖住院、严重低血糖住院。

临床怎么用

  • 在2型糖尿病合并不同衰弱状态的患者中,选择GLP-1受体激动剂或SGLT2抑制剂时,多数临床结局相当,但需关注GLP-1受体激动剂相关的透析或肾移植风险及轻度衰弱者的严重高血糖住院风险。
  • 建议根据患者衰弱状态制定和更新GLP-1受体激动剂与SGLT2抑制剂的使用指南,以改善2型糖尿病管理。

局限性

  • 本研究为回顾性观察性研究,可能存在残余混杂。
  • 研究基于台湾全民健康保险数据库,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: GLP-1 receptor agonists and SGLT2 inhibitors are increasingly being used in people with type 2 diabetes on the basis of findings from randomised clinical trials; however, little is known of whether clinical outcomes are affected by frailty in real-world settings. We aimed to compare the clinical effectiveness and safety of GLP-1 receptor agonists and SGLT2 inhibitors in managing type 2 diabetes, with a specific focus on stratifying people by their frailty status. METHODS: In this retrospective, nationwide, longitudinal study, we identified people (aged ≥20 years) with type 2 diabetes who newly initiated either a GLP-1 receptor agonist or an SGLT2 inhibitor during the period Jan 1, 2017 to Dec 31, 2019 from the Taiwan National Health Insurance database. Individuals were excluded if they had been diagnosed with cancer, received dialysis for kidney failure, or had prescriptions for a GLP-1 receptor agonist or an SGLT2 inhibitor, within 1 year before the index date. Mortality data were collected from the Taiwan National Death Registry. Eligible individuals were categorised into three frailty subgroups-fit, mild frailty, and moderate or severe frailty-on the basis of the multimorbidity frailty index. Propensity score matching (1:1) was used to balance covariates between recipients of GLP-1 receptor agonists and SGLT2 inhibitors among each frailty subgroup. Clinical outcomes of interest included three-point major adverse cardiovascular events (non-fatal acute myocardial infarction, non-fatal stroke, and fatal cardiovascular disease), all-cause mortality, hospitalisation for heart failure, dialysis or renal transplant, severe diabetic foot complications, retinopathy, hospitalisation for severe hyperglycaemia, and hospitalisation for severe hypoglycaemia. The association between the use of a GLP-1 receptor agonist versus an SGLT2 inhibitor and the risk of the outcomes of interest among each frailty subgroup was examined using a subdistribution hazard model. FINDINGS: We identified 320 210 people with type 2 diabetes, of whom 280 163 met the eligibility criteria, who initiated either a GLP-1 receptor agonist (n=22 968; mean age 57·7 years [SD 13·9], 11 338 [49·4%] were female, and 11 630 [50·6%] were male) or SGLT2 inhibitor (n=257 195; mean age 58·8 years [12·3], 107 988 [42·0%] were female, and 149 207 [58·0%] were male) during 2017-19. After matching, 11 882, 7210, and 3414 pairs of GLP-1 receptor agonist and SGLT2 inhibitor users were assigned in the fit, mild frailty, and moderate or severe frailty subgroups. All clinical outcomes were comparable between users of GLP-1 receptor agonists and SGLT2 inhibitors among each frailty subgroup, except for a higher risk of hospitalisation for severe hyperglycaemia with GLP-1 receptor agonists than with SGLT2 inhibitors in the mild frailty subgroup (subdistribution hazard ratio 1·25 [95% CI 1·13-1·38]; p<0·0001) and a higher risk of dialysis or renal transplant with GLP-1 receptor agonists than with SGLT2 inhibitors in the fit (2·43 [1·82-3·23]; p<0·0001), mild frailty (3·93 [3·03 -5·09]; p<0·0001), and moderate or severe frailty (2·60 [2·03-3·31]; p<0·0001) subgroups. INTERPRETATION: Formulating clear and updated guidelines on the use of GLP-1 receptor agonists and SGLT2 inhibitors according to frailty status could improve management of type 2 diabetes. FUNDING: Ministry of Education, Taiwan.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Hsiao FY, Tan EC, Meng LC, et al. Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study. Lancet Healthy Longev. 2024. PMID: 39284334. doi:10.1016/j.lanhl.2024.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。